Literature DB >> 27549091

Gonadotropin-releasing hormone agonist with add-back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis.

Dong-Yun Lee1, Jee-Yeon Lee1, Jong-Wook Seo1, Byung-Koo Yoon1, DooSeok Choi2.   

Abstract

PURPOSE: This study was performed to compare the efficacy and tolerability of GnRH agonist with add-back therapy versus dienogest treatment for preventing pelvic pain recurrence after laparoscopic surgery for endometriosis.
METHODS: Sixty-four reproductive-aged women who underwent laparoscopic surgery for endometriosis received post-operative medical treatment with either GnRH agonist plus 17β-estradiol and norethisterone acetate (n = 28) or dienogest (n = 36) for 6 months. The pre- to post-treatment changes in pain were assessed using a visual analogue scale, and changes in quality-of-life and menopausal symptoms were measured by questionnaire.
RESULTS: Visual analogue scale pain score decreased significantly for both treatments with no significant differences between groups. Neither physical, psychological, social, and environmental components of quality-of-life nor menopausal rating scale score were significantly different between the two groups. Bone mineral density at the lumbar spine declined significantly in both treatment groups (-2.5 % for GnRH agonist plus add-back and -2.3 % for dienogest), with no significant difference between the two groups.
CONCLUSION: GnRH agonist and add-back therapy using 17β-estradiol and norethisterone acetate are as effective and tolerable as dienogest for the prevention of pelvic pain recurrence after laparoscopic surgery for endometriosis.

Entities:  

Keywords:  Add–back therapy; Dienogest; Endometriosis; GnRH agonist; Pain; Quality-of-life

Mesh:

Substances:

Year:  2016        PMID: 27549091     DOI: 10.1007/s00404-016-4184-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  8 in total

Review 1.  Current and Emerging Therapeutics for the Management of Endometriosis.

Authors:  Simone Ferrero; Fabio Barra; Umberto Leone Roberti Maggiore
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 2.  Hormonal treatments for endometriosis: The endocrine background.

Authors:  Silvia Vannuccini; Sara Clemenza; Margherita Rossi; Felice Petraglia
Journal:  Rev Endocr Metab Disord       Date:  2021-08-17       Impact factor: 9.306

3.  Dienogest Versus Leuprolide Acetate for Recurrent Pelvic Pain Following Laparoscopic Treatment of Endometriosis.

Authors:  Ahmed Mahmoud Abdou; Islam Mohamed Magdi Ammar; Amr Abd Almohsen Alnemr; Amr Ahmed Abdelrhman
Journal:  J Obstet Gynaecol India       Date:  2018-04-16

Review 4.  Reevaluating response and failure of medical treatment of endometriosis: a systematic review.

Authors:  Christian M Becker; William T Gattrell; Kerstin Gude; Sukhbir S Singh
Journal:  Fertil Steril       Date:  2017-07       Impact factor: 7.329

5.  Systematic review of quality of life measures in patients with endometriosis.

Authors:  Nicolas Bourdel; Pauline Chauvet; Valentina Billone; Giannis Douridas; Arnaud Fauconnier; Laurent Gerbaud; Michel Canis
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

Review 6.  Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis.

Authors:  R Wattanayingcharoenchai; S Rattanasiri; C Charakorn; J Attia; A Thakkinstian
Journal:  BJOG       Date:  2020-07-14       Impact factor: 6.531

7.  Comparative analysis of molecular signatures suggests the use of gabapentin for the management of endometriosis-associated pain.

Authors:  Brice Bellessort; Anne Bachelot; Virginie Grouthier; Camille De Lombares; Nicolas Narboux-Neme; Paolo Garagnani; Chiara Pirazzini; Simonetta Astigiano; Luca Mastracci; Anastasia Fontaine; Gladys Alfama; Evelyne Duvernois-Berthet; Giovanni Levi
Journal:  J Pain Res       Date:  2018-04-10       Impact factor: 3.133

8.  Daily Vaginal Application of Dienogest (Visanne©) for 3 Months in Symptomatic Deeply Infiltrating Rectovaginal Endometriosis: A Possible New Treatment Approach?

Authors:  Andreas D Ebert
Journal:  Case Rep Obstet Gynecol       Date:  2018-05-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.